date:Sep 17, 2015
pted by FDA as evidence for reduced risk for type 2 diabetes.
The petition underwent an initial review by the FDA and it was accepted for filing on July 8, 2015. After going through a public comment period, the petition is now under review as a qualified health claim. A final decision is expected in the first quarter of 2016 or later.
The AOAC Research Institute approved a method extension for the DuPont BAX System real-time PCR assay for Salmonella to include enrichment protocols using Actero